Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis.
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002986:Clinical Trials as Topic; D005032:Ethylestrenol / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005340:Fibrinogen; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010629:Phenformin / Q000494:pharmacology / Q000627:therapeutic use; D010919:Placebos; D012008:Recurrence; D013442:Sulfinpyrazone / Q000494:pharmacology / Q000627:therapeutic use; D013924:Thrombophlebitis / Q000097:blood / Q000188:drug therapy*; D014859:Warfarin / Q000494:pharmacology / Q000627:therapeutic use
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010919:Placebos; D014859:Warfarin; D005340:Fibrinogen; D006493:Heparin; D005032:Ethylestrenol; D010629:Phenformin; D013442:Sulfinpyrazone